Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
Spero Therapeutics schedules a webcast company presentation and one-on-one investor meetings at the September 2026 H.C. Wainwright conference.
Rhea-AI Summary
Spero Therapeutics (SPRO)/b) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City on September 15, 2026, at 1:30 PM ET.President and CEO Esther Rajavelu will deliver the company presentation, and Spero's leadership team will be available for one-on-one meetings. The presentation will be webcast, with access via Spero's website Events + Presentations page and a replay available for about 90 days.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 12 | Second-quarter results | Positive | +4.2% | Utebzi approval, royalty financing, and extended operating runway supported the update |
| Aug 05 | Inducement equity grant | Neutral | +0.8% | New employee received stock options and restricted stock units under Nasdaq rules |
| Aug 04 | Earnings date notice | Neutral | +2.4% | Company scheduled second-quarter results and a business update for August 12 |
| Jul 27 | Leadership appointment | Positive | -0.8% | Debra Jeske Zack joined as chief medical officer to lead clinical development |
| Jul 14 | Royalty financing | Positive | -22.0% | Non-dilutive financing and SP001 license expanded funding and pipeline access |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Four of the five recent events had reactions aligned with the event characterization, while the July 14 financing and July 27 leadership announcements diverged.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that Esther Rajavelu, President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Healthcare Conference, to be held in New York City, September 14th -16th, 2026. Spero's leadership team will also be available for one-on-one meetings at the conference.
Presentation Details:
| H.C. Wainwright 28th Annual Global Investment Conference | |
| Company Presentation: | September 15, 2026 |
| Time: | 1:30 PM ET |
| Location: | New York, NY |
| Webcast Link: | Company Presentation |
The webcast may also be accessed through Spero's website on the Events + Presentations page. A replay of the webcast will be available for approximately 90 days following the conference. To request a meeting or for more details about the conference please reach out to your institutional contact at H.C. Wainwright.
About Spero Therapeutics
Spero Therapeutics is a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for patients with serious immune-mediated diseases. The company’s lead program, SP001, is a third-generation, Fc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related disease, with potential for development in additional immunological & inflammatory diseases. For more information, visit www.sperotx.com.
Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@Sperotx.com
Media Inquiries:
media@sperotx.com
FAQ
When will Spero Therapeutics (SPRO) present at the H.C. Wainwright 28th Annual Global Investment Conference?
Spero Therapeutics is scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, at 1:30 PM ET in New York, NY. The company notes that its leadership team will also be available for one-on-one meetings during the event.
Where is the Spero Therapeutics (SPRO) presentation taking place during the H.C. Wainwright 2026 conference?
The Spero Therapeutics company presentation at the H.C. Wainwright 28th Annual Global Investment Conference will take place in New York, NY. The conference runs from September 14–16, 2026, with Spero's presentation scheduled for September 15 at 1:30 PM ET.
How can investors access the Spero Therapeutics (SPRO) webcast from the H.C. Wainwright 2026 conference?
The company presentation will be available via a webcast link and can also be accessed through Spero Therapeutics' website on the Events + Presentations page. A replay of the webcast will be available for approximately 90 days following the conference.
Will there be a replay of the Spero Therapeutics (SPRO) H.C. Wainwright 2026 conference presentation?
Yes. A replay of Spero Therapeutics' presentation at the H.C. Wainwright 28th Annual Global Investment Conference will be available for approximately 90 days after the conference. The replay can be accessed via the webcast and through the company's Events + Presentations webpage.
How can investors request a one-on-one meeting with Spero Therapeutics (SPRO) at the H.C. Wainwright 2026 conference?
To request a one-on-one meeting with Spero Therapeutics' leadership during the H.C. Wainwright 28th Annual Global Investment Conference, investors are directed to contact their institutional contact at H.C. Wainwright for scheduling and additional conference details.